Introduction

If you’re struggling with persistent knee pain caused by osteoarthritis, finding an effective treatment can transform your everyday life. Among the newer options available, Arthrosamid injections have shown real promise in easing discomfort. Understanding how long you can expect relief to last after an Arthrosamid injection is essential for making informed choices about your care. In this article, we explore the latest evidence on the duration of relief, drawing on the expertise of Professor Paul Lee, a leading orthopaedic specialist, and the personalised treatment approach offered by MSK Doctors.

What is Arthrosamid and How Does It Work?

Arthrosamid is an injectable hydrogel treatment, specially designed for people with knee osteoarthritis. It’s a soft, gel-like substance that is carefully injected into the knee joint to help cushion the bones and reduce the friction that causes pain and stiffness. By acting as a shock absorber and improving joint movement, Arthrosamid can help patients experience greater comfort and better function.

Professor Paul Lee, a respected figure in orthopaedics and rehabilitation, has contributed significant research into advanced joint treatments like Arthrosamid. His deep understanding of cartilage repair shapes the way this treatment is offered, ensuring patients receive the best possible results.

How Long Does the Pain Relief Last?

Studies show that many patients enjoy notable pain relief lasting between six and twelve months after an Arthrosamid injection. Improvements in joint function and mobility often accompany this reduction in discomfort, meaning daily activities become easier again. Most patients report feeling better within a few weeks of treatment.

A systematic review highlights this well: “Statistically significant data was identified in two studies at both 52 weeks and 13 months, indicating the efficacy of PAAG hydrogel at one year post injection.”

Even more encouraging, follow-up research from one study found “statistically significant results at 2 years,” demonstrating that the benefits may last even longer for some.

That said, how long relief lasts can vary from person to person. Factors such as the severity of your osteoarthritis, the health of your joint, and how active you are all play a part. For example, those with mild to moderate knee osteoarthritis and good joint health often experience longer-lasting benefits. Lifestyle habits, including maintaining a healthy weight and modifying activities, also help extend the treatment’s effects.

How Does Arthrosamid Compare to Other Injections?

Other common injections for knee osteoarthritis include corticosteroids and hyaluronic acid. Corticosteroids often provide quick relief but usually only for a few weeks or months, and frequent use is not generally recommended due to potential side effects. Hyaluronic acid injections help lubricate the joint and typically offer relief for three to six months.

In contrast, Arthrosamid tends to provide longer-lasting relief, sometimes up to a year. One clinical trial found “numerically superior data compared to hyaluronic acid,” indicating a promising edge for Arthrosamid.

More recent research comparing these treatments concluded that Arthrosamid “offers comparable short-term efficacy and modest advantage at 6 months. However, long-term superiority is limited.” The same study noted that while pain scores for hyaluronic acid and corticosteroids returned to baseline by 12 months, “iPAAG remained slightly improved.” This suggests that Arthrosamid may help maintain some level of relief longer than these alternatives.

At MSK Doctors, treatments are tailored to each patient’s needs. Specialist advice from experts like Professor Paul Lee ensures you receive the most suitable care based on your individual condition.

What to Expect After Your Arthrosamid Injection and How to Care for Your Knee

After your injection, it’s normal to experience some mild swelling or tenderness around the knee, which usually settles within a few days. It’s best to take it easy initially and gradually return to your usual activities as you feel comfortable. Follow-up appointments allow your healthcare team to monitor progress and adjust your care if needed.

To maximise and prolong the benefits of Arthrosamid, ongoing care is vital. This typically includes physiotherapy to strengthen muscles around the knee and regular assessments with your specialist. The team at MSK Doctors offers continuous support, ensuring your treatment plan adapts to your recovery and lifestyle.

Safety is always a priority. Recent studies confirm that “injection of PAAG hydrogel intraarticularly into the knee has been shown to be safe with no long-lasting adverse events reported.” In fact, laboratory research shows that this hydrogel “demonstrates no apparent neurotoxic or cytotoxic effects” when tested in human nerve cell cultures, reassuring patients and clinicians alike about its safety profile.

Conclusion

Arthrosamid injections provide a promising option for knee osteoarthritis sufferers, with pain relief typically lasting six to twelve months — and for some, even up to two years. While it compares favourably to other injections like corticosteroids and hyaluronic acid, its advantages over the longer term are modest, emphasising the importance of an individualised care plan. Consulting with specialists such as Professor Paul Lee and the MSK Doctors team can help determine if Arthrosamid is right for you. Remember, every patient’s experience is unique, and expert guidance is key to managing your knee health effectively.

References

• Cole, A., Maulana, R., Whitehead, J., & Lee, P. (2022). A systematic review of the novel compound Arthrosamid polyacrylamide (PAAG) hydrogel for treatment of knee osteoarthritis. Medical Research Archives, 10(8). https://doi.org/10.18103/mra.v10i8.2950
• Aykaç, B., Dinç, M., Nar, Ö. O., Karasu, R., & Bayrak, H. Ç. (2025). Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. Medicine, 104(16), e44655. https://doi.org/10.1097/MD.0000000000044655
• Walmod, P. S., Kusk, P., Jøhnk, N., Ankorina‐Stark, I., & Essex, A. (2025). An injectable 2.5% cross-linked polyacrylamide hydrogel (2.5 iPAAG) demonstrates no neurotoxicity in human induced pluripotent stem cells-derived iCell® GlutaNeurons. Frontiers in Toxicology. https://doi.org/10.3389/ftox.2025.1585430